Novavax Initiates Pivotal Phase 3 Trial of the RSV F Vaccine in Older Adults

Go back to Novavax Initiates Pivotal Phase 3 Trial of the RSV F Vaccine in Older Adults
Novavax, Inc. (NASDAQ: NVAX) Delayed: 10.02 -0.99 (8.99%)
Previous Close $11.01    52 Week High $9.23 
Open $10.79    52 Week Low $1.16 
Day High $10.87    P/E N/A 
Day Low $9.56    EPS $-0.30 
Volume 10,471,508